ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Blockade of HLA Antibody-Triggered Classical Complement Activation by High-Affinity Humanized Monoclonal Anti-C1s Antibody TNT009 – Results of a First-in-Human Phase 1 Trial.

J. Mühbacher,1 B. Jilma,2 M. Wahrmann,3 L. Marinova,3 F. Eskandary,3 J. Gilbert,4 S. Panicker,4 G. Böhmig.3

1Department of Surgery, Medical University of Vienna, Vienna, Austria
2Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
3Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria
4True North Therapeutics, Inc., South San Francisco, CA.

Meeting: 2016 American Transplant Congress

Abstract number: 414

Keywords: Dosage, HLA antibodies, Immunosuppression, Rejection

Session Information

Session Name: Concurrent Session: Kidney Immunosuppression: Novel Agents

Session Type: Concurrent Session

Date: Tuesday, June 14, 2016

Session Time: 2:30pm-4:00pm

 Presentation Time: 2:54pm-3:06pm

Location: Veterans Auditorium

Study purpose: Classical complement may play a key role in ABMR. A promising therapeutic approach could be complement inhibition at the level of key component C1. In this single ascending dose part of a first-in-human phase 1 trial (NCT02502903) we evaluated the tolerability and activity of TNT009, a high-affinity humanized monoclonal antibody directed against serine protease C1s. Methods: In a double-blind, randomized, placebo-controlled phase 1 trial, 48 healthy volunteers received either a single dose of TNT009 or placebo by IV infusion (3:1 randomization; 7 cohorts: 0.3-100 mg/kg). To determine the effect of TNT009 on ex vivo HLA antibody-triggered complement activation, serum samples from dosed subjects were added as a complement source in a modified solid phase assay. C3d deposition was detected on HLA haplotype-coated flow beads pre-incubated with pooled inactivated sera obtained from sensitized patients. Results were expressed as the mean of C3d MFI determined on 16 defined bead populations. Results. Single doses of 3-100 mg/kg TNT009 led to a >85% inhibition of HLA antibody-triggered C3d bead deposition. At doses of 10, 30, 60 or 100 mg/kg this effect lasted for 2 to at least 14 days. C3d test results showed a tight dose-effect relationship without major inter-individual differences. Similarly, in vitro spiking of sera with TNT009 revealed uniform and strong complement inhibition at concentrations >30 [mu]g/mL. Conclusion. We demonstrate that TNT009 allows for prolonged and complete classical pathway inhibition in vivo. Future studies will clarify whether TNT009 is able to block antibody-mediated injury as a strategy to prevent or treat ABMR.

CITATION INFORMATION: Mühbacher J, Jilma B, Wahrmann M, Marinova L, Eskandary F, Gilbert J, Panicker S, Böhmig G. Blockade of HLA Antibody-Triggered Classical Complement Activation by High-Affinity Humanized Monoclonal Anti-C1s Antibody TNT009 – Results of a First-in-Human Phase 1 Trial. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Mühbacher J, Jilma B, Wahrmann M, Marinova L, Eskandary F, Gilbert J, Panicker S, Böhmig G. Blockade of HLA Antibody-Triggered Classical Complement Activation by High-Affinity Humanized Monoclonal Anti-C1s Antibody TNT009 – Results of a First-in-Human Phase 1 Trial. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/blockade-of-hla-antibody-triggered-classical-complement-activation-by-high-affinity-humanized-monoclonal-anti-c1s-antibody-tnt009-results-of-a-first-in-human-phase-1-trial/. Accessed May 21, 2025.

« Back to 2016 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences